UNITY BIOTECHNOLOGY INC (UBX) Stock Price, Quote, News and Overview
NASDAQ:UBX - Nasdaq - US91381U2006 - Common Stock - Currency: USD
UBX Quote, Performance and Key Statistics
UNITY BIOTECHNOLOGY INC
NASDAQ:UBX (2/4/2025, 8:13:03 PM)
After market: 2.23 0 (0%)2.23
+0.06 (+2.76%)
The current stock price of UBX is 2.23 USD. In the past month the price increased by 74.22%. In the past year, price increased by 24.58%.
UBX Latest News, Press Releases and Analysis
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Top movers analysis in the middle of the day on 2025-01-23: top gainers and losers in today's session.
UNITY Biotechnology Reports Granting of New Employment Inducement Award
UNITY Biotechnology Reports Granting of New Employment Inducement Award
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing...
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to...
UBX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 15.04 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About UBX
Company Profile
Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 19 full-time employees. The company went IPO on 2018-05-03. The firm is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. The company is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence and is advancing senolytic programs primarily in ophthalmologic disorders. In addition, it has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1967 is its back-up compound to UBX1325. UBX2089, an α-Klotho hormone drug candidate, which is being researched for multiple neurology indications.
Company Info
UNITY BIOTECHNOLOGY INC
285 East Grand Avenue
South San Francisco CALIFORNIA US
Employees: 19
Company Website: https://unitybiotechnology.com/
Investor Relations: https://ir.unitybiotechnology.com/
Phone: 16504161192
UBX FAQ
What is the stock price of UBX?
The current stock price of UBX is 2.23 USD.
What is the symbol for UNITY BIOTECHNOLOGY INC stock?
The exchange symbol of UNITY BIOTECHNOLOGY INC is UBX and it is listed on the Nasdaq exchange.
On which exchange is UBX stock listed?
UBX stock is listed on the Nasdaq exchange.
Is UBX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for UBX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of UBX.
Does UBX stock pay dividends?
UBX does not pay a dividend.
What is the Price/Earnings (PE) ratio of UBX?
UBX does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.31).
What is the Short Interest ratio of UBX stock?
The outstanding short interest for UBX is 1.34% of its float.
UBX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to UBX. When comparing the yearly performance of all stocks, UBX is one of the better performing stocks in the market, outperforming 94.15% of all stocks.
UBX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to UBX. While UBX seems to be doing ok healthwise, there are quite some concerns on its profitability.
UBX Financial Highlights
Over the last trailing twelve months UBX reported a non-GAAP Earnings per Share(EPS) of -1.31. The EPS increased by 59.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.05% | ||
| ROE | -141.02% | ||
| Debt/Equity | 0 |
UBX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to UBX. The Buy consensus is the average rating of analysts ratings from 7 analysts.